These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35910221)

  • 1. SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma.
    Zhou Q; Wei M; Shen W; Huang S; Fan J; Huang H
    Front Genet; 2022; 13():899883. PubMed ID: 35910221
    [No Abstract]   [Full Text] [Related]  

  • 2. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
    Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
    Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioinformatic Analyses Identify a Prognostic Autophagy-Related Long Non-coding RNA Signature Associated With Immune Microenvironment in Diffuse Gliomas.
    Xu S; Tang L; Liu Z; Yang K; Cheng Q
    Front Cell Dev Biol; 2021; 9():694633. PubMed ID: 34211979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
    Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
    Front Oncol; 2020; 10():586019. PubMed ID: 33425739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas.
    Yan X; Zhou Q; Zhu H; Liu W; Xu H; Yin W; Zhao M; Jiang X; Ren C
    iScience; 2021 Nov; 24(11):103249. PubMed ID: 34755091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic biomarker SYK and its correlation with immune infiltrates in glioma.
    Wang C; Liu P; Sun Y; Liu T; Xu X; Guo J; Gong Z; Sun H; Xu R
    Exp Ther Med; 2023 Oct; 26(4):499. PubMed ID: 37810632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
    Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
    Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TANK shapes an immunosuppressive microenvironment and predicts prognosis and therapeutic response in glioma.
    Li S; Guo Y; Hu H; Gao N; Yan X; Zhou Q; Liu H
    Front Immunol; 2023; 14():1138203. PubMed ID: 37215097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma.
    Xiong Y; Qi Y; Pan Z; Wang S; Li B; Feng B; Xue H; Zhao R; Li G
    Cancer Cell Int; 2022 Sep; 22(1):294. PubMed ID: 36163046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
    Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
    Front Oncol; 2021; 11():650153. PubMed ID: 34055619
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hu Z; Qu S
    Front Immunol; 2021; 12():683572. PubMed ID: 34267752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
    Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
    Front Oncol; 2022; 12():889351. PubMed ID: 36033495
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis.
    Xu Z; Chen X; Song L; Yuan F; Yan Y
    Front Immunol; 2022; 13():834595. PubMed ID: 35281049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
    Li J; Wang J; Ding Y; Zhao J; Wang W
    BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas.
    Chen S; Zhang S; Wang Z; Li J; Yuan Y; Li T; Zuo M; Feng W; Li W; Chen M; Liu Y
    Front Pharmacol; 2022; 13():1038272. PubMed ID: 36438805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
    Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
    Front Oncol; 2021; 11():654350. PubMed ID: 33954112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma.
    Yuan Y; Yang B; Qi Z; Han Z; Cai J; Song J
    Front Oncol; 2022; 12():783721. PubMed ID: 35814367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
    Peng Y; Liu H; Wu Q; Wang L; Yu Y; Yin F; Feng C; Ren X; Liu T; Chen L; Zhu H
    BMC Cancer; 2023 Jun; 23(1):596. PubMed ID: 37380984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.